No Data
No Data
Biological Drugs Strategic Research Report 2024-2030, Profiles of 45+ Players Including Abbott Laboratories, Amgen, Baxter, Biogen, BMS, Eli Lilly and Co, GSK, Merck, Novartis, and Pfizer
Live Stock: If It only Takes ~$6M for a Singularity, Why is the Market Paying $500B?
FDA Approves Leqembi Four-week Maintenance Dosing
Sage Rejects Biogen Bid, Launches Review of Alternatives
Sage Therapeutics Remains Focused on the Goal of Establishing Zurzuvae as Standard of Care for Women With Postpartum Depression >SAGE
Sage Therapeutics Board of Directors Initiates Review of Strategic Alternatives and Rejects Biogen's Unsolicited Acquisition Proposal